KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Financing Activities: 2018-2025

Historic Cash from Financing Activities for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to -$919,000.

  • Castle Biosciences' Cash from Financing Activities fell 209.67% to -$919,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.8 million, marking a year-over-year decrease of 194.27%. This contributed to the annual value of $6.1 million for FY2024, which is 367.15% up from last year.
  • Per Castle Biosciences' latest filing, its Cash from Financing Activities stood at -$919,000 for Q3 2025, which was down 1,009.90% from $101,000 recorded in Q2 2025.
  • Castle Biosciences' 5-year Cash from Financing Activities high stood at $10.6 million for Q1 2024, and its period low was -$5.4 million during Q4 2024.
  • For the 3-year period, Castle Biosciences' Cash from Financing Activities averaged around $133,636, with its median value being $45,000 (2023).
  • In the last 5 years, Castle Biosciences' Cash from Financing Activities tumbled by 695.24% in 2022 and then surged by 1,762.22% in 2024.
  • Over the past 5 years, Castle Biosciences' Cash from Financing Activities (Quarterly) stood at $126,000 in 2021, then slumped by 695.24% to -$750,000 in 2022, then slumped by 339.60% to -$3.3 million in 2023, then plummeted by 63.33% to -$5.4 million in 2024, then plummeted by 209.67% to -$919,000 in 2025.
  • Its last three reported values are -$919,000 in Q3 2025, $101,000 for Q2 2025, and -$1.6 million during Q1 2025.